Breaking News

MRM Health Closes $64M Series B Financing Round

Proceeds will enable MRM Health to complete a Phase 2b clinical trial for its lead program MH002 in patients suffering from mild-to-moderate ulcerative colitis.

Author Image

By: Charlie Sternberg

Associate Editor

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, has closed a $64 million Series B financing round. The round was led by French pharmaceutical group Biocodex and included strong participation from German-based ATHOS, as well as new investor BNP Paribas Fortis Private Equity and existing investors SFPIM, Ackermans & van Haaren (AvH), OMX Europe Venture Fund (OMX), Qbic II and VIB. Proceeds w...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters